Bulging late-stage R&D pipelines suggest many in the cell and gene therapy sector are preparing to go market. For such firms, having the right manufacturing infrastructure will be vital for commercial success, says Ken Green from Vertex. Commercializing a cell or gene therapy is a complex process. Once a therapy is approved, the developer has to manufacture it and bring it to market in a stable and sustainable way. “The big question for us as an industry is how are…
Twist Bioscience will begin shipping synthetic genes from its Portland, Oregon production plant in January, after investing around $87 million over the past two years. For the full fiscal year 2022, DNA synthesis firm Twist Bioscience reported total revenues of $203.6 million and orders of $226 million, respectively up 54% and 42% year-on-year. This included around $80 million in gene production for Twist’s partner SynBio, a collaboration inked in 2017 that sees Twist manufacture synthetic DNA up to 3.2 kilobases in length…
Just six months after accepting the role, Mark Womack is no longer serving as the CEO of KBI Biopharma and Selexis. The firm released a statement detailing that Tim Lowery, president of JSR Life Sciences, has been appointed as interim CEO as the company searches to identify someone for a permanent position. The reasons behind his departure have not been disclosed despite BioProcess Insider reaching out to Womack directly for additional information. However, a spokesperson for KBI told us that…
Thermo Fisher Scientific has introduced the Gibco CTS adeno-associated virus (AAV)- MAX Helper Free production system, which it says can save time and reduce costs by 50%. According to the firm, the all-in-one solution production system is “the only product of its kind that is manufactured under cGMP conditions to enable large-scale applications.” Additionally, Thermo says that the system has been designed to meet both clinical and commercial demands of AAV-based gene therapies, as well as bringing products to market…